Hims & Hers Health's chief legal officer sells $7.46 million in stock

Boughton Soleil, the Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), executed a series of stock transactions on January 6, 2025, according to a recent SEC filing. Soleil sold a total of 268,932 shares of Class A Common Stock, with prices ranging from $27.72 to $28.00 per share. The total value of the shares sold amounted to approximately $7.46 million.

In addition to these sales, Soleil also exercised stock options, acquiring a total of 254,023 shares at prices between $2.43 and $5.01 per share. These transactions were conducted under a Rule 10b5-1 trading plan established in August 2024. Following these transactions, Soleil holds 169,803 shares of Hims & Hers Health.

In other recent news, Hims & Hers Health has been the subject of several significant developments. The company reported a 77% year-over-year increase in Q3 sales, surpassing $400 million, and an adjusted EBITDA over $50 million. Revenue projections for Q4 2024 range between $465 million and $470 million, marking a significant year-over-year increase. Analyst firms BTIG and Morgan Stanley (NYSE:MS) have initiated coverage on Hims & Hers Health with a Buy and Overweight rating respectively, while Needham & Company named it their top pick for 2025.

These firms highlight the company's robust revenue growth, innovative business model, and strong demand for its health services. Additionally, Hims & Hers Health announced a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound. However, the FDA's resolution of the tirzepatide injection shortage may impact market dynamics for obesity drugs, potentially affecting companies like Hims & Hers Health.

In a similar vein, digital health company Ro also announced a collaboration with Eli Lilly, aiming to facilitate access to Zepbound. These partnerships underscore the ongoing efforts by companies to enhance access to approved obesity treatments. These are just some of the recent developments that are shaping the trajectory of Hims & Hers Health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.